Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification

Liu,Jiayu; He,Yuhao; Zhang,Xuebin; Yan,Xiaoling; Huang,Ying

doi:10.3892/ol.2020.11263

Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification

Authors:
- Jiayu Liu
- Yuhao He
- Xuebin Zhang
- Xiaoling Yan
- Ying Huang
View Affiliations

Affiliations: Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300000, P.R. China, Department of Neurosurgery, Third People's Hospital of Chengdu, Chengdu, Sichuan 610000, P.R. China, Department of Pathology, Tianjin Huanhu Hospital, Tianjin 300000, P.R. China
Published online on: January 8, 2020 https://doi.org/10.3892/ol.2020.11263
Pages: 1890-1898
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary adenomas (PAs) are a common subtype of intracranial tumors. The aim of the present study was to analyse the clinical and pathological features of different types of pituitary adenomas (PAs) according to the 2017 World Health Organisation Endocrine Organ Tumor Classification guidelines. The clinical data of 250 patients with PAs were collected and analysed. Differences in the incidence of invasion, recurrence and apoplexy in patients between high‑ and low‑risk PAs were compared, as were differences in the Ki‑67 index between invasive and non‑invasive PAs and between recurrent PAs and non‑recurrent PAs. Of the 250 cases, 45 cases were diagnosed as somatotroph adenomas, 26 cases as lactotroph adenomas, 1 case as thyrotroph adenoma, 61 cases as corticotroph adenomas, 93 cases as gonadotropin adenomas, 15 cases as null cell adenomas and 9 cases as plurihormonal adenomas. There were 5 types of high‑risk pituitary adenoma identified: 17 cases of sparsely granulated somatotroph adenoma, 11 cases of lactotroph adenoma in men, 3 cases of plurihormonal PIT‑1 positive adenoma and 42 cases of silent corticotroph adenoma. Crooke's cell adenoma was not identified. High‑risk PAs had significantly higher rates of invasion, recurrence and apoplexy compared with that in low‑risk types (P<0.001). Invasive PAs had a significantly higher Ki‑67 index compared with that in non‑invasive PAs (3.5±1.8 vs. 2.8±1.3; P<0.01). Recurrent PAs had a significantly higher Ki‑67 index compared with that in non‑recurrent PAs (3.9±1.9 vs. 2.8±1.3; P<0.001). According to the 2017 classification criteria, patients most frequently had gonadotrophin cell adenomas, followed by corticotroph adenomas and the proportion of null cell adenomas was reduced. Differences were noted in the proliferation, recurrence and apoplexy characteristics of high‑risk PAs and low‑risk PAs. The invasion and recurrence of PAs were found to be related to the Ki‑67 index.

View Figures

View References

1	Kovacs K: The 2004 WHO classification of pituitary tumors: Comments. Acta Neuropathol. 111:62–63. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lopes MBS: The 2017 world health organization classification of tumors of the pituitary gland: A summary. Acta Neuropathol. 134:521–535. 2017. View Article : Google Scholar : PubMed/NCBI
3	Asa SL, Bamberger AM, Cao B, Wong M, Parker KL and Ezzat S: The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 81:2165–2170. 1996. View Article : Google Scholar : PubMed/NCBI
4	Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, Gavrilina G and Milbrandt J: Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science. 273:1219–1221. 1996. View Article : Google Scholar : PubMed/NCBI
5	Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA and Parker KL: Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function. Development. 128:147–154. 2001.PubMed/NCBI
6	Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A and Drouin J: A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 104:849–859. 2001. View Article : Google Scholar : PubMed/NCBI
7	Scully KM and Rosenfeld MG: Pituitary development: Regulatory codes in mammalian organogenesis. Science. 295:2231–2235. 2002. View Article : Google Scholar : PubMed/NCBI
8	Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Enjalbert A, Drouin J and Brue T: Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. J Clin Endocrinol Metab. 88:3050–3056. 2003. View Article : Google Scholar : PubMed/NCBI
9	Sjöstedt E, Bollerslev J, Mulder J, Lindskog C, Pontén F and Casar-Borota O: A specific antibody to detect transcription factor T-Pit: A reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol. 134:675–677. 2017. View Article : Google Scholar : PubMed/NCBI
10	Luo X, Ikeda Y and Parker KL: A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell. 77:481–490. 1994. View Article : Google Scholar : PubMed/NCBI
11	Dasen JS, O'Connell SM, Flynn SE, Treier M, Gleiberman AS, Szeto DP, Hooshmand F, Aggarwal AK and Rosenfeld MG: Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell. 97:587–598. 1999. View Article : Google Scholar : PubMed/NCBI
12	Manojlovic-Gacic E, Engstrom BE and Casar-Borota O: Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary. 21:119–129. 2018. View Article : Google Scholar : PubMed/NCBI
13	Kontogeorgos G, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Smyth HS and Rologis D: Double adenomas of the pituitary: A clinicopathological study of 11 tumors. Neurosurgery. 31:840–849. 1992. View Article : Google Scholar : PubMed/NCBI
14	Raappana A, Koivukangas J, Ebeling T and Pirilä T: Incidence of pituitary adenomas in northern Finland in 1992–2007. J Clin Endocrinol Metab. 95:4268–4275. 2010. View Article : Google Scholar : PubMed/NCBI
15	Buurman H and Saeger W: Subclinical adenomas in postmortem pituitaries: Classification and correlations to clinical data. Eur J Endocrinol. 154:753–758. 2006. View Article : Google Scholar : PubMed/NCBI
16	Eremkina AK, Dzeranova LK, Pigarova EK, Mokrysheva NG and Dedov II: Morphofunctional features of non-functioning pituitary adenomas. Arkh Patol. 81:71–78. 2019.(In Russian). View Article : Google Scholar : PubMed/NCBI
17	García-Sáenz M, Uribe-Cortés D, González-Virla B, Mendoza-Zubieta V and Vargas-Ortega G: Silent pituitary plurihormonal adenoma: Clinical relevance of immunohistochemical analysis. Rev Med Inst Mex Seguro Soc. 57:48–55. 2019.(In English and Spanish). PubMed/NCBI
18	Pappy AL II, Savinkina A, Bicknese C, Neill S, Oyesiku NM and Ioachimescu AG: Predictive modeling for pituitary adenomas: Single center experience in 501 consecutive patients. Pituitary. 22:520–531. 2019. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Zhang X, Yan X, Sun M, Fan Y and Huang Y: Significance of TERT and ATRX mutations in glioma. Oncol Lett. 17:95–102. 2019.PubMed/NCBI
20	Micko AS, Wohrer A, Wolfsberger S and Knosp E: Invasion of the cavernous sinus space in pituitary adenomas: Endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 122:803–811. 2015. View Article : Google Scholar : PubMed/NCBI
21	Andujar-Plata P, Villar-Taibo R, Ballesteros-Pomar MD, Vidal-Casariego A, Pérez-Corral B, Cabezas-Agrícola JM, Álvarez-Vázquez P, Serramito R and Bernabeu I: Long-term outcome of multimodal therapy for giant prolactinomas. Endocrine. 55:231–238. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chatzellis E, Alexandraki KI, Androulakis II and Kaltsas G: Aggressive pituitary tumors. Neuroendocrinology. 101:87–104. 2015. View Article : Google Scholar : PubMed/NCBI
23	Mou C, Han T, Zhao H, Wang S and Qu Y: Clinical features and immunohistochemical changes of pituitary apoplexy. J Clin Neurosci. 16:64–68. 2009. View Article : Google Scholar : PubMed/NCBI
24	Tapar K, Kovach K and Khorvat E: Classification, pathology and molecular biology of pituitary adenoma. Arkh Patol. 59:7–17. 1997.(In Russian). PubMed/NCBI
25	Klimstra DS: Pathology reporting of neuroendocrine tumors: Essential elements for accurate diagnosis, classification, and staging. Semin Oncol. 40:23–36. 2013. View Article : Google Scholar : PubMed/NCBI
26	Inoshita N and Nishioka H: The 2017 WHO classification of pituitary adenoma: Overview and comments. Brain Tumor Pathol. 35:51–56. 2018. View Article : Google Scholar : PubMed/NCBI
27	Cooper O and Melmed S: Subclinical hyperfunctioning pituitary adenomas: The silent tumors. Best Pract Res Clin Endocrinol Metab. 26:447–460. 2012. View Article : Google Scholar : PubMed/NCBI
28	Chalkley MD, Kiupel M and Draper AC: Pituitary null cell adenoma in a domestic llama (Lama glama). J Comp Pathol. 151:51–56. 2014. View Article : Google Scholar : PubMed/NCBI
29	Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J and Dekkers OM; European Society of Endocrinology, : European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 178:G1–G24. 2018. View Article : Google Scholar : PubMed/NCBI
30	Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR and Biller BM; Pasireotide B2305 Study Group, : A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 366:914–924. 2012. View Article : Google Scholar : PubMed/NCBI
31	Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J and Inoshita N: Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: A single-center study of 90 cases. J Neurosurg. 121:1462–1473. 2014. View Article : Google Scholar : PubMed/NCBI
32	Mortini P, Losa M, Barzaghi R, Boari N and Giovanelli M: Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery. 56:1222–1233. 2005. View Article : Google Scholar : PubMed/NCBI
33	Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y and Yamada S: The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 26:349–355. 2015. View Article : Google Scholar : PubMed/NCBI
34	Arafah BM and Nasrallah MP: Pituitary tumors: Pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 8:287–305. 2001. View Article : Google Scholar : PubMed/NCBI
35	Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M and Benediktsson R: The epidemiology of pituitary adenomas in Iceland, 1955–2012: A nationwide population-based study. Eur J Endocrinol. 173:655–664. 2015. View Article : Google Scholar : PubMed/NCBI
36	Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S and Asa SL: Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 29:131–142. 2016. View Article : Google Scholar : PubMed/NCBI
37	Manojlovic-Gacic E, Bollerslev J and Casar-Borota O: Invited Review: Pathology of pituitary neuroendocrine tumours: Present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. Neuropathol Appl Neurobiol. 2019. View Article : Google Scholar : PubMed/NCBI
38	Dworakowska D and Grossman AB: Aggressive and malignant pituitary tumours: State-of-the-art. Endocr Relat Cancer. 25:R559–R575. 2018. View Article : Google Scholar : PubMed/NCBI
39	Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD and Kovacs K: Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin North Am. 44:99–104. 2015. View Article : Google Scholar : PubMed/NCBI
40	Pizarro CB, Oliveira MC, Coutinho LB and Ferreira NP: Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res. 37:235–243. 2004. View Article : Google Scholar : PubMed/NCBI
41	Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J and Reincke M: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: Correlation with growth velocity and invasiveness. J Neurosurg. 99:674–679. 2003. View Article : Google Scholar : PubMed/NCBI
42	Marques P, Mafra M, Calado C, Martins A, Monteiro J and Leite V: Aggressive pituitary lesion with a remarkably high Ki-67. Arq Bras Endocrinol Metabol. 58:656–660. 2014. View Article : Google Scholar : PubMed/NCBI
43	Del Basso De Caro M, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G and Cappabianca P: Atypical pituitary adenomas: Clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev. 40:105–114. 2017. View Article : Google Scholar : PubMed/NCBI
44	Klibanski A: Clinical practice. Prolactinomas. N Engl J Med. 362:1219–1226. 2010. View Article : Google Scholar : PubMed/NCBI
45	Sheehan J, Rainey J, Nguyen J, Grimsdale R and Han S: Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg. 114:354–358. 2011. View Article : Google Scholar : PubMed/NCBI
46	Chen XY, Wang Z, Li B, Zhang YJ and Li YY: Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells. Biochem Biophys Res Commun. 473:296–302. 2016. View Article : Google Scholar : PubMed/NCBI
47	Batista RL, Trarbach EB, Marques MD, Cescato VA, da Silva GO, Herkenhoff CGB, Cunha-Neto MB and Musolino NR: Nonfunctioning pituitary adenoma recurrence and its relationship with sex, size, and hormonal immunohistochemical profile. World Neurosurg. 120:e241–e246. 2018. View Article : Google Scholar : PubMed/NCBI
48	Lee JYK, Cho SS, Zeh R, Pierce JT, Martinez-Lage M, Adappa ND, Palmer JN, Newman JG, Learned KO, White C, et al: Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. J Neurosurg. 129:390–403. 2018. View Article : Google Scholar : PubMed/NCBI
49	Mitrofanova LB, Vorobeva OM and Gorshkov AN: Analysis of pituitary adenoma expression patterns suggests a potential role for the NeuroD1 transcription factor in neuroendocrine tumor-targeting therapies. Oncotarget. 10:289–312. 2019. View Article : Google Scholar : PubMed/NCBI
50	Wang S, Ding C, Xiao D, Wu Z and Wei L: Evaluation of a novel general pituitary hormone score to evaluate the function of the residual anterior pituitary (adenohypophysis) in patients following surgery for pituitary adenoma. Med Sci Monit. 24:7944–7951. 2018. View Article : Google Scholar : PubMed/NCBI